Related references
Note: Only part of the references are listed.Post-treatment levels of -fetoprotein predict long-term hepatocellular carcinoma development after sustained virological response in patients with hepatitis C
Toshifumi Tada et al.
HEPATOLOGY RESEARCH (2017)
NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b
Eiichi Ogawa et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan
Norio Akuta et al.
JOURNAL OF MEDICAL VIROLOGY (2017)
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors
Tatsuo Kanda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C
Hiroko Nagata et al.
JOURNAL OF HEPATOLOGY (2017)
EASL Recommendations on Treatment of Hepatitis C 2016
JOURNAL OF HEPATOLOGY (2017)
APASL consensus statements and recommendation on treatment of hepatitis C
Masao Omata et al.
HEPATOLOGY INTERNATIONAL (2016)
Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients
Eisuke Miyaki et al.
HEPATOLOGY RESEARCH (2016)
Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies
M. Mizokami et al.
JOURNAL OF VIRAL HEPATITIS (2016)
Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure
Jun Itakura et al.
PLoS One (2016)
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
Masashi Mizokami et al.
LANCET INFECTIOUS DISEASES (2015)
Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay
Satoshi Yoshimi et al.
PLOS ONE (2015)
Post-treatment Levels of α-Fetoprotein Predict Incidence of Hepatocellular Carcinoma After Interferon Therapy
Tsugiko Oze et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Efficacy of daclatasvir in hepatitis C virus
Namiki Izumi
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2014)
Elevated Serum Levels of Wisteria floribunda Agglutinin-Positive Human Mac-2 Binding Protein Predict the Development of Hepatocellular Carcinoma in Hepatitis C Patients
Kazumi Yamasaki et al.
HEPATOLOGY (2014)
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
Hiromitsu Kumada et al.
HEPATOLOGY (2014)
Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection
Mika Miura et al.
HEPATOLOGY RESEARCH (2014)
A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors
Yoshihito Uchida et al.
PLOS ONE (2014)
α-Fetoprotein Levels After Interferon Therapy and Risk of Hepatocarcinogenesis in Chronic Hepatitis C
Yasuhiro Asahina et al.
HEPATOLOGY (2013)
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
Yoshiyuki Suzuki et al.
JOURNAL OF HEPATOLOGY (2013)
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
Kazuaki Chayama et al.
HEPATOLOGY (2012)
Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus
Masakuni Tateyama et al.
JOURNAL OF GASTROENTEROLOGY (2011)
Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A meta-analysis of diagnostic accuracy
E. A. Tsochatzis et al.
JOURNAL OF HEPATOLOGY (2011)
Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC
Hidenori Toyoda et al.
JOURNAL OF HEPATOLOGY (2008)
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and FibroTest
Adays Vallet-Pichard et al.
HEPATOLOGY (2007)
A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades
Y Tanaka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
